openPR Logo
Press release

Pharmacelsus' GLP implementation exemplary for European CROs

06-04-2009 03:20 PM CET | Health & Medicine

Press release from: Pharmacelsus GmbH

Scientists of the European Center for Validation of Alternative Methods (ECVAM) attended a GLP workshop at Pharmacelsus GmbH

Saarbrücken, 4. Juni 2009 - Pharmacelsus, a CRO specialized in preclinical test services, obtained GLP-certification covering the complete portfolio in November 2008. The company is not only able to perform accompanying analytical services for clinical studies in addition to its preclinical services, but also decided to share its knowledge on the GLP implementation process with other laboratories. Thirteen scientists of the European Commission Joint Research Center came to learn more about Pharmacelsus' solution for the implementation of a GLP system in an /in vitro/ laboratory. During a three days hands-on training, they glanced at the lab-life in theory and practice, especially focusing the GLP relevant implementation on /in vitro/ toxicology and bioanalytics. The practical course provided the opportunity for staff of all levels to understand the importance and relevance of GLP compliance, and how to apply the requirements of GLP into their everyday work in an /in vitro/ laboratory.

Pharmacelsus cooperates with ECVAM in the framework of an international pre-validation study in the field of human metabolism and toxicity which is supervised by ECVAM.

Pharmacelsus offers a wide range of biological, analytical and pharmacological studies for pharmaceutical and biotechnological companies with a focus on preclinical test services. Pharmacelsus holds the statement of GLP compliance for categories 2 (toxicity studies), 8 (analytical and clinical chemistry testing) and 9 (other studies: pharmacodynamic, pharmacokinetic, metabolical and toxicological testing). Because of the GLP status, the company is now able to perform accompanying analytical services for clinical studies in addition to its preclinical services.

Pressekontakt: Kontakt:

Dr. Stefanie Becker Pharmacelsus GmbH
Business Development / Sales Manager Science Park 2

Telefon: +49 (0)681 / 39 46 - 75 16 66123 Saarbrücken
Telefax: +49 (0)681 / 39 46 - 75 11 Telefon: +49 (0)681 / 39 46 - 75 10



This announcement is originally distributed by Hugin.
The issuer is solely responsible for the content of this announcement.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pharmacelsus' GLP implementation exemplary for European CROs here

News-ID: 82629 • Views:

More Releases from Pharmacelsus GmbH

Active Pharmaceutical Ingredients/API Sales Market Size, Share and Forecast till 2022
Active Pharmaceutical Ingredients/API Sales Market Size, Share and Forecast till …
In this report, the global Active Pharmaceutical Ingredients/API market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our business development executive can get in touch with you. Request Sample

More Releases for GLP

GLP Analogs Market Report, History and Forecast 2020-2026|Novo Nordisk, AstraZen …
" Los Angeles, United States – – QY Research offers an overarching research and analysis-based study on the global GLP Analogs market, covering growth prospects, market development potential, profitability, supply and demand, and other important subjects. The report presented here comes out as a highly reliable source of information and data on the global GLP Analogs market. The researchers and analysts who have prepared the report used an advanced research methodology
Glucagon Like Peptide-1 (GLP-1) Agonists Market - key players covered:GSK, Sanof …
Los Angeles, United State, –The report titled Global Glucagon Like Peptide-1 (GLP-1) Agonists Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer
In safe hands with the GLP checklist
The "Good Laboratory Practice" regulatory mandate (GLP for short) was introduced in 1978 after the FDA (U.S. Food and Drug Administration) had already identified significant deficiencies in toxicological studies in the years preceding. The German Chemicals Act was introduced in an effort to ensure that newly approved drugs for human consumption really are safe and minimize any and all risks. The values of transparency, traceability, assignment of responsibilities, and safekeeping are
Glucagon-Like Peptide-1 (Glp-1) Analogs Market | Global Opportunity Analysis, 20 …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
The Global Report Focuses on Glucagon Like Peptide-1 (GLP-1) Agonists Market 201 …
"The Report Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -" The Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report is a professional and in-depth study on the current state of the Glucagon like peptide-1 (GLP-1) agonists industry. The report provides a basic overview of the industry including definitions, classifications, applications and
Sysmex Europe and GLP Systems to attend Euromedlab
Norderstedt, Germany, 21 May 2013 – Healthcare solution specialist Sysmex Europe and lab automation experts GLP Systems recently announced their long-term cooperation in the field of laboratory automation. Now both companies are attending Euromedlab in Milan from 19-23 May – and are looking forward to answering any queries. With a brand new transport concept, modular solutions and real freedom from manufacturers, they are confident they are introducing a game changer